Day One Biopharmaceuticals Inc reported in the third quarter of 2025 net loss per share of $-0.19 compare to earnings per share of $0.38 in the same quarter a year ago and improved compare to net loss per share of $-0.29 realized in previous quarter.
third quarter of 2025
Earnings Per Share
Revenues
$ -0.19
$
40 Mill
$-0.57
$-54M-57.56 %
Day One Biopharmaceuticals Inc 's Revenue
fell by
-57.56 % in third quarter of 2025 (Sep 30 2025) year on year,
to $40 million and
advanced by
17.36 % sequentially.
Day One Biopharmaceuticals Inc in the third quarter of 2025 recorded net loss of $-39.452 million, compare to net income of $73.192 million achieved in III. Quarter a year ago.
Sequentially
net loss narrowed from net loss of $-60.644 million realized in previous quarter.
Day One Biopharmaceuticals Inc Inventories Inventories grew by 158.17 % to $7 million from III. Quarter a year ago, sequentially inventories rose by 7.92 %.
DAWN's Cash flow
In the third quarter of 2025 company's net cash flow was $8 million
Day One Biopharmaceuticals Inc
does not pay out common stock dividend.
In trailing twelve-month period Day One Biopharmaceuticals Inc payed $ -1.16 cash per share, on a free-cash flow basis
.
Book value fell by -2.46 % sequentially to $4.36 per share, -5.60% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 4.18 per share from $ 4.28.
Company
issued 0.31 million shares or 0.30 % in Sep 30 2025.
Day One Biopharmaceuticals Inc
does not pay out common stock dividend.
In trailing twelve-month period Day One Biopharmaceuticals Inc had negative $ -1.16 cash flow per share, on a free-cash flow basis
.
Book value fell by -2.46 % sequentially to $4.36 per share, -5.60% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 4.18 per share from $ 4.28.
Company
issued 0.31 million shares or 0.30 % in Sep 30 2025.
With the release of the second quarter results for Day One Biopharmaceuticals Inc, it is evident that the company is currently experiencing some financial challenges. The Major Pharmaceutical Preparations sector consultants have observed an operating shortfall of $-49.254 million, indicating that the company has not generated any revenue during the April to June 30, 2023 quarter. This presents a significant contrast to the same period last year, where the operating shortfall was $-36.719 million. However, it is crucial to note that Day One Biopharmaceuticals Inc reported a net deficit of $0.000 million in the second quarter of 2023, compared to a deficit of $-36.530 million in the corresponding period a ...
